Breast Cancer Clinical Trial
Official title:
A Single-arm, Multicenter, Proof-of-concept Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium Despite Recent Treatment With IV Bisphosphonates
Verified date | September 2018 |
Source | Amgen |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to determine the potential of denosumab to treat Hypercalcemia of Malignancy in patients with elevated serum calcium who do not respond to recent treatment with intravenous bisphosphonates by lowering corrected serum calcium </= 11.5 mg/dL (2.9 millimoles /L) by day 10.
Status | Completed |
Enrollment | 33 |
Est. completion date | August 21, 2013 |
Est. primary completion date | September 13, 2012 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Hypercalcemia of Malignancy (HCM) as defined as documented histologically or cytologically confirmed cancer and a corrected serum calcium (CSC) > 12.5 mg/dL (3.1 millimoles /L) at screening by local laboratory - Last IV bisphosphonate treatment must be >/= to 7 days and </= to 30 days before the screening corrected serum calcium - Adults (>/=18 years) - Adequate organ function as defined by the following criteria: - serum aspartate aminotransferase (AST) </= 5 x upper limit of normal (ULN) - serum alanine aminotransferase (ALT) </= 5 x upper limit of normal - serum total bilirubin </= 2 x upper limit of normal Exclusion Criteria: - Evidence of benign hyperparathyroidism, hyperthyroidism, adrenal insufficiency, vitamin D intoxication, milk alkali syndrome, sarcoidosis, or other granulomatous disease - Receiving dialysis for renal failure - Treatment with thiazides, calcitonin, mithramycin, or gallium nitrate within their window of expected therapeutic effect (as determined by the physician) prior to the date of the screening CSC - Treatment with cinacalcet within 4 weeks prior to the date of the screening CSC - Thirty days or less since receiving an investigational product (other than denosumab) or device (ie, does not have marketing authorization; thalidomide use is allowed) in another clinical study - Known sensitivity to any of the products to be administered during the study (eg, mammalian derived products) - Female subject is pregnant or breast feeding, or planning to become pregnant within 7 months after the end of treatment - Female subject of childbearing potential is not willing to use 2 highly effective methods of contraception during treatment and for 7 months after the end of treatment - Subject will not be available for follow-up assessment. - Any organic or psychiatric disorder that, in the opinion of the investigator, might prevent the subject from completing the study or interfere with the interpretation of the study results |
Country | Name | City | State |
---|---|---|---|
Canada | Research Site | Québec | Quebec |
Canada | Research Site | Québec | Quebec |
France | Research Site | Limoges Cedex | |
France | Research Site | Montpellier Cedex 5 | |
France | Research Site | Nantes Cedex 1 | |
France | Research Site | Villejuif cedex | |
Italy | Research Site | Bologna | |
Italy | Research Site | Firenze | |
Italy | Research Site | Milano | |
Italy | Research Site | Padova | |
Italy | Research Site | Roma | |
Poland | Research Site | Warszawa | |
United States | Research Site | Bronx | New York |
United States | Research Site | Dearborn | Michigan |
United States | Research Site | Detroit | Michigan |
United States | Research Site | Durham | North Carolina |
United States | Research Site | Encinitas | California |
United States | Research Site | Goldsboro | North Carolina |
United States | Research Site | Houston | Texas |
United States | Research Site | New Haven | Connecticut |
United States | Research Site | New York | New York |
United States | Research Site | Omaha | Nebraska |
United States | Research Site | Salisbury | Maryland |
United States | Research Site | Syracuse | New York |
Lead Sponsor | Collaborator |
---|---|
Amgen |
United States, Canada, France, Italy, Poland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of Participants With a Response Within 10 Days of First Dose of Denosumab | Response is defined as corrected serum calcium (CSC) = 11.5 mg/dL, within 10 days after the first dose of denosumab. For all CSC values, if albumin was < 4 g/dL, the following formula was used to calculate CSC: CSC = Total serum calcium [mg/dL] + (0.8 x (4 - serum albumin [g/dL])) | 10 days | |
Secondary | Percentage of Participants With a Response by Visit | Response is defined as corrected serum calcium (CSC) = 11.5 mg/dL, within 10 days after the first dose of denosumab. For all CSC values, if albumin was < 4 g/dL, the following formula was used to calculate CSC: CSC = Total serum calcium [mg/dL] + (0.8 x (4 - serum albumin [g/dL])) | Days 2, 4, 8, 10, 15, 19, 23, 29, 36, 43, 50 and 57 | |
Secondary | Percentage of Participants With a Complete Response by Visit | Response is defined as corrected serum calcium (CSC) = 10.8 mg/dL (2.7 mmol/L). For all CSC values, if albumin was < 4 g/dL, the following formula was used to calculate CSC: CSC = Total serum calcium [mg/dL] + (0.8 x (4 - serum albumin [g/dL])). | Days 2, 4, 8, 10, 15, 19, 23, 29, 36, 43, 50 and 57 | |
Secondary | Time to Response | Time to Response was defined as the time period from study Day 1 to the first time post-baseline corrected serum calcium (CSC) = 11.5 mg/dL. Participants were censored on the last CSC assessment day if no response was observed. If there was no post-baseline CSC assessment, time to response was censored on study Day 1. Time to response was analyzed using Kaplan-Meier methods. |
From Day 1 until the end of study date or primary data cutoff date (13 September 2012), whichever occured first; median time on study was 1.8 months. | |
Secondary | Time to Complete Response | Time to complete response was defined as the time period from study Day 1 to the first time post-baseline corrected serum calcium (CSC) was = 10.8 mg/dL (2.7 mmol/L). Participants were censored on the last CSC assessment day if no complete response was observed. If there was no post-baseline CSC assessment, time to complete response was censored on study Day 1. Time to complete response was analyzed using Kaplan-Meier methods. | From Day 1 until the end of study date or primary data cutoff date (13 September 2012), whichever occured first; median time on study was 1.8 months. | |
Secondary | Duration of Response | Duration of response is defined as the number of days from the first day of corrected serum calcium = 11.5 mg/dL (2.9 millimoles/L) to the last day of corrected serum calcium = 11.5 mg/dL. Participants were censored on the last CSC assessment day if their CSC level never reached > 11.5 mg/dL after the first response. If a participant had no CSC assessment after the first response, duration of response was set to zero and censored. Duration of response was summarized for participants who achieved a response using the Kaplan-Meier method. | From Day 1 until the end of study date or primary data cutoff date (13 September 2012), whichever occured first; median time on study was 1.8 months. | |
Secondary | Duration of Complete Response | Duration of complete response is defined as the number of days from the first day of of corrected serum calcium = 10.8 mg/dL (2.7 millimoles/L) to the last day of corrected serum calcium = 10.8 mg/dL. Participants were censored on the last CSC assessment day if their CSC level never reached > 10.8 mg/dL after the complete response. If a participant had no CSC assessment after the complete response, duration of complete response was set to zero and censored. Duration of complete response was summarized for participants who achieved a complete response using the Kaplan-Meier method. | From Day 1 until the end of study date or primary data cutoff date (13 September 2012), whichever occured first; median time on study was 1.8 months. | |
Secondary | Time to Relapse/Nonresponse of Hypercalcemia of Malignancy | Time to relapse/nonresponse was defined as the number of days from study Day 1 until the last day of CSC = 11.5 mg/dL for all particiipants with relapse after the first response. Participants were censored on the last CSC assessment day if their CSC level never reached > 11.5 mg/dL after first response. For participants who never achieved response, time to relapse/nonresponse was set to zero. Otherwise, if there was no post-baseline CSC assessment, time to relapse/nonresponse was censored on study Day 1. Time to relapse/nonresponse was estimated using the Kaplan-Meier method. | From Day 1 until the end of study date or primary data cutoff date (13 September 2012), whichever occured first; median time on study was 1.8 months. | |
Secondary | Change From Baseline in Corrected Serum Calcium | Baseline and Days 2, 4, 8, 10, 15, 19, 23, 29, 36, 43, 50 and 57 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |